264 related articles for article (PubMed ID: 17482893)
21. Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene.
Chung J; Scherer LJ; Gu A; Gardner AM; Torres-Coronado M; Epps EW; Digiusto DL; Rossi JJ
Mol Ther; 2014 May; 22(5):952-63. PubMed ID: 24576853
[TBL] [Abstract][Full Text] [Related]
22. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression.
Ball CR; Pilz IH; Schmidt M; Fessler S; Williams DA; von Kalle C; Glimm H
Blood; 2007 Sep; 110(6):1779-87. PubMed ID: 17496202
[TBL] [Abstract][Full Text] [Related]
23. Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones.
Jansen M; Bardenheuer W; Sorg UR; Seeber S; Flasshove M; Moritz T
Eur J Haematol; 2001 Jul; 67(1):2-13. PubMed ID: 11553261
[TBL] [Abstract][Full Text] [Related]
24. In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector.
Cai S; Ernstberger A; Wang H; Bailey BJ; Hartwell JR; Sinn AL; Eckermann O; Linka Y; Goebel WS; Hanenberg H; Pollok KE
Exp Hematol; 2008 Mar; 36(3):283-92. PubMed ID: 18279716
[TBL] [Abstract][Full Text] [Related]
25. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro.
Zielske SP; Gerson SL
Mol Ther; 2002 Apr; 5(4):381-7. PubMed ID: 11945064
[TBL] [Abstract][Full Text] [Related]
26. Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.
Maze R; Kurpad C; Pegg AE; Erickson LC; Williams DA
J Pharmacol Exp Ther; 1999 Sep; 290(3):1467-74. PubMed ID: 10454526
[TBL] [Abstract][Full Text] [Related]
27. Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance.
Torres ID; Loureiro JA; Coelho MAN; Carmo Pereira M; Ramalho MJ
Expert Opin Drug Deliv; 2022 Nov; 19(11):1397-1415. PubMed ID: 36103209
[TBL] [Abstract][Full Text] [Related]
28. In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations.
Pollok KE; Hartwell JR; Braber A; Cooper RJ; Jansen M; Ragg S; Bailey BJ; Erickson LC; Kreklau EL; Williams DA
Hum Gene Ther; 2003 Dec; 14(18):1703-14. PubMed ID: 14670122
[TBL] [Abstract][Full Text] [Related]
29. Lentiviral MGMT(P140K)-mediated in vivo selection employing a ubiquitous chromatin opening element (A2UCOE) linked to a cellular promoter.
Phaltane R; Lachmann N; Brennig S; Ackermann M; Modlich U; Moritz T
Biomaterials; 2014 Aug; 35(25):7204-13. PubMed ID: 24875758
[TBL] [Abstract][Full Text] [Related]
30. Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation.
Hacke K; Falahati R; Flebbe-Rehwaldt L; Kasahara N; Gaensler KM
Immunol Res; 2009; 44(1-3):112-26. PubMed ID: 19048410
[TBL] [Abstract][Full Text] [Related]
31. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo.
Moritz T; Mackay W; Glassner BJ; Williams DA; Samson L
Cancer Res; 1995 Jun; 55(12):2608-14. PubMed ID: 7780976
[TBL] [Abstract][Full Text] [Related]
32. Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection.
Baum C; Eckert HG; Stockschläder M; Just U; Hegewisch-Becker S; Hildinger M; Uhde A; John J; Ostertag W
J Hematother; 1996 Aug; 5(4):323-9. PubMed ID: 8877707
[TBL] [Abstract][Full Text] [Related]
33. Reversal of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced severe immunodeficiency by transduction of murine long-lived hemopoietic progenitor cells using O6-methylguanine DNA methyltransferase complementary DNA.
Maze R; Kapur R; Kelley MR; Hansen WK; Oh SY; Williams DA
J Immunol; 1997 Jan; 158(2):1006-13. PubMed ID: 8993023
[TBL] [Abstract][Full Text] [Related]
34. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
Larochelle A; Choi U; Shou Y; Naumann N; Loktionova NA; Clevenger JR; Krouse A; Metzger M; Donahue RE; Kang E; Stewart C; Persons D; Malech HL; Dunbar CE; Sorrentino BP
J Clin Invest; 2009 Jul; 119(7):1952-63. PubMed ID: 19509470
[TBL] [Abstract][Full Text] [Related]
35. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
Kaina B; Christmann M; Naumann S; Roos WP
DNA Repair (Amst); 2007 Aug; 6(8):1079-99. PubMed ID: 17485253
[TBL] [Abstract][Full Text] [Related]
36. Chemoselection of allogeneic HSC after murine neonatal transplantation without myeloablation or post-transplant immunosuppression.
Falahati R; Zhang J; Flebbe-Rehwaldt L; Shi Y; Gerson SL; Gaensler KM
Mol Ther; 2012 Nov; 20(11):2180-9. PubMed ID: 22871662
[TBL] [Abstract][Full Text] [Related]
37. Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse model.
Phaltane R; Haemmerle R; Rothe M; Modlich U; Moritz T
Hum Gene Ther; 2014 Feb; 25(2):144-55. PubMed ID: 24218991
[TBL] [Abstract][Full Text] [Related]
38. Genetic manipulation of drug sensitivity in haematopoietic cells.
Southgate T; Fairbairn LJ
Expert Rev Mol Med; 2004 Aug; 6(18):1-24. PubMed ID: 15387894
[TBL] [Abstract][Full Text] [Related]
39. In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.
Gori JL; Beard BC; Ironside C; Karponi G; Kiem HP
Cancer Gene Ther; 2012 Aug; 19(8):523-9. PubMed ID: 22627392
[TBL] [Abstract][Full Text] [Related]
40. Tumor-associated mutations in O⁶ -methylguanine DNA-methyltransferase (MGMT) reduce DNA repair functionality.
Lamb KL; Liu Y; Ishiguro K; Kwon Y; Paquet N; Sartorelli AC; Sung P; Rockwell S; Sweasy JB
Mol Carcinog; 2014 Mar; 53(3):201-10. PubMed ID: 23065697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
